Related Experiment Videos
Cyclin-dependent kinase inhibitors for treating cancer
1Department of Medicinal Chemistry, Pfizer Global Research & Development, Ann Arbor Laboratories, Ann Arbor, Michigan 48105, USA. Peter.toogood2@pfizer.com
Abstract:
Cyclin dependent kinases (Cdks) are essential enzymes for the control of cell cycle progression. Inhibitors of cyclin-dependent kinases are anticipated to possess therapeutic utility against a wide variety of proliferative diseases, especially cancer. The field of published small molecule Cdk inhibitors is briefly reviewed here as background to a summary of work on a class of pyrido[2,3-d]pyrimidine Cdk inhibitors. Compounds from this class are described that display potency against cyclin D/Cdk4 up to IC(50) = 0.004 microM. Good to moderate selectivity for cyclin D/Cdk4 is also reported for compounds in this structural class. Structure-activity relationship data are presented for substitution at the C2 and N8 positions and these data are interpreted in the context of a binding model that is based on the Cdk2 crystal structure. A representative cyclin D/Cdk4 inhibitor (compound 56) is demonstrated to selectively inhibit the proliferation of an Rb(+) cell line vs. a matched Rb(-) cell line and to produce a distinct G(1) block consistent with cyclin D/Cdk4 inhibition in cells.
Insights
New pyrido[2,3-d]pyrimidine compounds show potent inhibition of cyclin D/cyclin-dependent kinase 4 (Cdk4), offering potential cancer therapies. These cyclin-dependent kinase inhibitors selectively block cell proliferation in Rb(+) cells.
Area of Science:
- Biochemistry
- Molecular Biology
- Medicinal Chemistry
Background:
- Cyclin-dependent kinases (Cdks) regulate cell cycle progression.
- Cdk inhibitors are investigated for treating proliferative diseases, particularly cancer.
- Small molecule inhibitors targeting Cdks are a key area of pharmaceutical research.
Purpose of the Study:
- To review published small molecule Cdk inhibitors.
- To summarize research on a specific class of pyrido[2,3-d]pyrimidine Cdk inhibitors.
- To evaluate the therapeutic potential of these compounds against cancer.
Main Methods:
- Synthesis and characterization of pyrido[2,3-d]pyrimidine compounds.
- In vitro enzymatic assays to determine inhibitory potency (IC50) against cyclin D/Cdk4.
- Cell-based proliferation assays using Rb(+) and Rb(-) cell lines.
- Structure-activity relationship (SAR) analysis.
- Molecular modeling based on Cdk2 crystal structure.
Main Results:
- Pyrido[2,3-d]pyrimidine compounds exhibit high potency against cyclin D/Cdk4 (IC50 down to 0.004 microM).
- Compounds show good to moderate selectivity for cyclin D/Cdk4.
- SAR data for C2 and N8 substitutions provide insights into binding.
- A representative inhibitor (compound 56) selectively inhibited Rb(+) cell proliferation and induced a G1 cell cycle block.
Conclusions:
- Pyrido[2,3-d]pyrimidine derivatives are potent and selective inhibitors of cyclin D/Cdk4.
- These findings support the therapeutic potential of this compound class for cancer treatment.
- The study provides a basis for further optimization of Cdk inhibitors.